SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
Hepatitis
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
Longitudinal Phenotypic Profiling of Early HCV-Specific CD4 T Cells in HIV- and HIV+ Individuals
Diana Y. Chen
Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States
Rapid Peripheral In Vivo Cellular Changes During Interferon-Free Treatment of Hepatitis C
Eric G. Meissner
Laboratory of Immunoregulation, NIAID/NIH, Bethesda, MD, United States
Faldaprevir Plus Pegylated Interferon Alfa-2a/Ribavirin in HIV/HCV Coinfection: STARTVerso4
Douglas Dieterich
Mount Sinai Medical Center, New York, NY, United States
Simeprevir (TMC435) Plus PegIFN/Ribavirin in HCV Genotype-1/HIV-1 Coinfection (Study C212)
Douglas Dieterich
Icahn School of Medicine at Mount Sinai, New York, NY, United States
All-Oral Combination of Daclatasvir, Asunaprevir, and BMS-791325 for HCV Genotype 1 Infection
Trevor Hawkins
Southwest CARE Center, Santa Fe, NM, United States
Sofosbuvir Plus Ribavirin for HCV Genotype 1-3 Infection in HIV Coinfected Patients (PHOTON-1)
Susanna Naggie
Duke Clinical Research Institute, Durham, NC, United States
Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Final Results of the SYNERGY Trial
Anita Kohli
Critical Care Medicine Department, National Institutes of Health, Bethesda, MD, United States and Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC–Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD, United States
Daclatasvir in Combination With Simeprevir ± Ribavirin for Hepatitis C Virus Genotype 1 Infection
Christophe Hezode
Hôpital Henri Mondor, Paris, France
PEARL III: SVR ≥99% After 12 Wks of ABT-450/r/267 + ABT-333 ± RBV in Treatment Naïve HCV GT1b Infection
K Rajender Reddy
University of Pennsylvania, Philadelphia, PA, United States
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
